Navigation Links
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
Date:2/29/2008

in short-term studies of major depressive disorder and other psychiatric disorders. Patients of all ages started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. SEROQUEL and SEROQUEL XR are not approved for use in patients under the age of 18 years. SEROQUEL XR is not approved for the treatment of depression; however, SEROQUEL is approved for the treatment of bipolar depression. (See Boxed Warning.)

Hyperglycemia, in some cases extreme and associated with ketoacidosis, hyperosmolar coma, or death, has been reported in patients treated with atypical antipsychotics, including quetiapine. The relationship of atypical use and glucose abnormalities is complicated by the possibility of increased risk of diabetes in the schizophrenic population and the increasing incidence of diabetes in the general population. However, epidemiological studies suggest an increased risk of treatment-emergent, hyperglycemia-related adverse events in patients treated with atypical antipsychotics. Patients starting treatment with atypical antipsychotics who have or are at risk for diabetes should undergo fasting blood glucose testing at the beginning of and periodically during treatment. Patients who develop symptoms of hyperglycemia should also undergo fasting blood glucose testing.

A potentially fatal symptom complex, sometimes referred to as Neuroleptic Malignant Syndrome (NMS), has been reported in association with administration of antipsychotic drugs, including quetiapine. Rare cases of NMS have been reported with quetiapine. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status, and evidence of autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myog
'/>"/>

SOURCE AstraZeneca
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pediatric Asthma Programs Featuring PARI Pharmas eFlow Acquired by AstraZeneca
2. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
3. AstraZeneca and Banner Alzheimers Institute Collaborate to Evaluate New Tool Targeting Alzheimers Disease
4. Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development
5. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
6. AstraZeneca Response to February 21, 2008 Ruling In Re: Alabama Medicaid Pharmaceutical AWP Litigation - cv2005-219 - Circuit Court of Montgomery, Alabama
7. Exelixis Submits XL880 Diligence Report to GlaxoSmithKline
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. AMDL Submits Data to FDA for Clearance to Market Its DR-70(R) Diagnostic Test to Monitor Colorectal Cancer Patients
11. Cephalon Submits Supplemental New Drug Application for FENTORA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Feb. 27, 2015  Steep Hill, the industry leader ... internationally, intends to open a full service medical cannabis ... , bringing advanced scientific tools and methodology to ... Steep Hill is currently the only laboratory licensed by ... and contaminant testing in order to meet the recently ...
(Date:2/26/2015)... Feb. 26, 2015 On behalf of biotech ... companies, Wilentz, Goldman & Spitzer, P.A. (Wilentz) ... against Genewiz Inc. in excess of $10 million. The ... trade secrets, and that it improperly hired one or ... denying motions for judgment notwithstanding the verdict, a new ...
(Date:2/26/2015)... Mass., Feb. 26, 2015   Synageva BioPharma ... biopharmaceutical company developing therapeutic products for rare disorders, ... provided 2015 goals, other key objectives, and financial ... call today at 4:30 p.m. EST to review ... update.  To participate in today,s call by telephone, ...
(Date:2/26/2015)... Fla. , Feb. 26, 2015 DuPont ... growth priorities driven by key research advancements and product ... at today,s Bank of America Merrill Lynch 2015 Global ... the challenge of building grain supplies the last two ... continue at the pace of the last decade, when ...
Breaking Biology Technology:Steep Hill First to Receive Provisional Approval to Establish Laboratory Services for Cannabis Testing in State of New Mexico 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 2DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 3DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 4DuPont Leader Outlines Path for Growth in Agriculture and Nutrition & Health Segments 5
... NEW YORK and BANGALORE, India , May ... (TB Alliance) and AstraZeneca announced today at the 2010 BIO ... agreement to accelerate the discovery, development and clinical use of ... disease. One in five patients with TB are resistant to ...
... ... medicine company developing solutions based on the products of newborn cells grown under embryonic ... (ICSCE). Analysis of the cells grown under Histogen,s proprietary conditions of hypoxia and low ... , ...
... ... to develop new feedstocks with greater sustainability and volume, such as Jatropha ... demand, of biodiesel CJP’s R & D centre started studying and identifying ... identified, developed and cultivated as many as 14 non-food oil crops. ...
Cached Biology Technology:TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 2TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 3TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis 4Hypoxia Induces Stem Cell Gene Expression, Protein Production and Cell Surface Markers 2Hypoxia Induces Stem Cell Gene Expression, Protein Production and Cell Surface Markers 3CJP Assesses Pongamia, Moringa, Castor, Simarouba, Algae etc. as New Sustainable Biodiesel Crops 2CJP Assesses Pongamia, Moringa, Castor, Simarouba, Algae etc. as New Sustainable Biodiesel Crops 3CJP Assesses Pongamia, Moringa, Castor, Simarouba, Algae etc. as New Sustainable Biodiesel Crops 4
(Date:2/9/2015)... Feb. 9, 2015  Lintec of America recently announced ... carbon nanotube (CNT) macrostructures, including sheets, yarns and ribbons, ... Leveraging the vast industrial resources of the ... , Lintec of America is forming the Nano-Science ... , focusing on scaling up the manufacturing and ...
(Date:2/5/2015)... 5, 2015  Marken is starting its 35 th ... launched a new marketing campaign to solidify its place ... new campaign focuses on First as a ... The first headline in the series, ... with its client,s priorities. Marken recognizes the need to ...
(Date:2/5/2015)... --NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... on the growing mobile commerce market, announces the launch ... part of its 2015 marketing and branding initiatives for ... consumer website for Wocketwallet.com earlier this month. ... "Our new corporate website naturally showcases our premiere consumer ...
Breaking Biology News(10 mins):Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4Marken Launches New Patient-Centric Campaign 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... underlying brain skills needed to think, remember and learn are ... fact of life for most older Americans. ... critically important for lessening declines in mental performance as people ... efforts aimed at preventing or delaying cognitive decline, dietary modifications ...
... on biomarkers of cardiovascular disease: implications for heart-healthy diets," ... , examined 26 clinical studies and two meta-analyses to ... Of the probiotics examined, L. reuteri NCIMB 30242 ... (TLC) dietary requirements by: , Significantly ...
... , Fires in and around Snowy River National Park in ... (MODIS) aboard the Aqua satellite on February 06, 2014. Actively ... red. Hot, dry, windy conditions in Victoria have been ... territory. The fires in this image are located in ...
Cached Biology News:Nutritional supplement improves cognitive performance in older adults, study finds 2Nutritional supplement improves cognitive performance in older adults, study finds 3Heart health through gut health 2
... introduce its new line of Protein Standards, ... for use in mass spectrometry, molecular biology, ... Standards are high quality purified proteins for ... by electrospray ionization mass spectrometry (ESI-MS). ...
... N,N- bis- (3-D-Gluconamidopropyl)deoxycholamide White ... CHAPS and CHAPSO. Has reduced electrostatic interactions ... chromatography on DEAE-cellulose. Aggregation number: 8-16. ... H 2 O. Aggregation number 8 - ...
Determine relative degree of protein binding to phosphoinositides...
Goat Anti-Horse IgG(T) Antibody, Unconjugated...
Biology Products: